US to buy 1.4M courses of Merck's COVID-19 drug

Tuesday, 09. November 2021 12:18

Merck & Co. Inc. announced on Tuesday that the United States government will purchase 1.4 million more courses of treatment of its COVID-19 treatment molnupiravir, pending authorization. In total, the US has so far committed to buying a total of 3.1 million courses worth around $2.2 billion, with further options to buy another two million. Merck expects to produce 10 million courses by the end of this year and at least 20 million in 2022.

Last month, Merck and Ridgeback Biotherapeutics filed for emergency use authorization in the US for the pill after the phase 3 trial showed it reduced the risk of hospitalization or death related to COVID-19 by approximately 50%. The Food and Drugs Administration (FDA) should discuss the application on November 30.

Related Links: Merck KGaA
Baha Breaking News (BBN) / DJ